India, Dec. 5 -- The Pharma Solutions business of Piramal Enterprises Limited, a leading development and contract manufacturing company (CDMO), announced that the company is going to Associate with BerGenBio ASA to develop bemcentinib for the treatment of elderly patients with recurrent acute myeloid leukemia (AML).Bemcentinib has recently been designated as a fasttrackdrug by the US Food and Drug Administration (FDA), as for the patients with recurrent AML, there are currently no marketed drugs specifically approved for use in Canada.

Peter DeYoung,CEO of Piramal Pharma Solutions, said, "The fact that BerGenBio decided to partner with us validates our integrated business model.The breadth and depth of our assets and the expertise we hav...